Elizabeth Neyens, PhD
With 20 years of experience as a Board-certified toxicological pathologist and a DVM, Dr. Elizabeth Neyens has dedicated their career to advancing drug development. They began as a staff pathologist at Merck and Charles River Preclinical Drug Development, followed by serving as Head of Pathology at Baxter in Europe. During a pivotal year in Israel, she worked as a consultant, supporting an IPO transition, before returning to North America to become a Professor of Pathology at Einstein Medical University in New York.
A recognized expert in biologics, Elizabeth played a advisory role in guiding the preclinical pipeline for JUV-161. Her professional focus lies in delivering GLP-compliant preclinical development programs, conducting peer reviews, and supporting successful IND submissions. Driven by a passion for translating innovative molecules into clinical success, they are committed to making global healthcare advancements accessible to patients worldwide.
Learn more about Elizabeth
